Zilucoplan Production Cost Reports

The report provides a detailed analysis essential for establishing a Zilucoplan manufacturing plant. It encompasses all critical aspects necessary for Zilucoplan production, including the cost of Zilucoplan production, Zilucoplan plant cost, Zilucoplan production costs, and the overall Zilucoplan manufacturing plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Zilucoplan production plant. These encompass manufacturing processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Zilucoplan is a small synthetic macrocyclic peptide, and it serves as an inhibitor of complement component C5. It is used for the treatment of generalized myasthenia gravis in adults who are not responsive to anti-acetylcholine receptor antibodies. It works by binding to C5 protein and preventing its cleavage into lytic products, stopping activation of the terminal complement pathway.  By doing so, the inflammatory responses are decreased, which provides improvement of symptoms such as muscle weakness and fatigue seen in patients having myasthenia gravis. Zilucoplan is being studied for its uses for other immune-mediated necrotizing myopathy (IMNM) and additional complement-mediated illness. It appears to be a promising addition in the treatment of different autoimmune diseases that may become useful as an effective therapeutic option.

The industrial Zilucoplan procurement is driven by its use as first generation complement C5 inhibitor approved for generalized myasthenia gravis treatment. Its use for treatment-refractory patient populations seeking more effective therapies contributes to its demand. Its utilization as an important treatment for MG, as evidenced in clinical trials, makes it a sought-after therapeutic option for patients who do not respond well to existing therapies such as steroids or other immunosuppressants.

It is more convenient and appealing to patients when compared with intravenous therapies, which further contributes to its demand. The company’s effort to make it available in a wide range of countries with regulatory activity also makes it a drug with high demand across the globe. Overall, the market of Zilucoplan C5 inhibitor in treating myasthenia gravis, its demonstrated efficacy, the convenience of subcutaneous administration, and global availability efforts.

Raw Material for Zilucoplan Production

According to the Zilucoplan manufacturing plant project report, the key raw materials used in the production of Zilucoplan include Amino acids-Wang Resin-Solvents-Palmitic Acid.

Manufacturing Process of Zilucoplan

The extensive Zilucoplan production cost report consists of the following major industrial manufacturing process:

1. From Amino acids, Wang resin, Solvents, and palmitic acid: The industrial manufacturing process for Zilucoplan involves a solid-phase peptide synthesis. First, amino acids are attached to wang resin one by one. After that, the connection is formed between two amino acids, and the end of the chain is modified. Then, the peptide is removed from the resin and labeled with palmitic acid. Finally, the product is purified to obtain pure Zilucoplan.

Zilucoplan is a colorless solution. Its molecular formula is C172H278N24O55, and it has a molecular weight of around 3562.229 Da. It contains 15 amino acids, including four unnatural amino acids. It is stable against proteolytic degradation due to its cyclic structure. It is supplied as a sodium salt and has good solubility in aqueous solutions. It is metabolized into smaller peptides and amino acids that contribute to its pharmacokinetics. It is kept at -20°C for short-term use and at -80°C for long-term preservation. All these physical and chemical properties contribute to its pharmaceutical activity.